REMM Bibliography - Medical Management of Radiation Injury (Exposure) - Radiation Emergency Medical Management

REMM Bibliography - Medical Management of Radiation Injury (Exposure) - Radiation Emergency Medical Management

Management of febrile neutropenia

Introduction

• In clinical oncology, diagnosis and treatment of fever and neutropenia is a common problem. Many clinical practice guidelines and evidence reviews have been published, with periodic updates as understanding of the pathophysiology improves, and new drugs and regimens are introduced.
• During a mass casualty radiation emergency, diagnosis and treatment of fever and neutropenia will surely occur among those who receive a high enough dose from exposure to whole- or partial-body radiation.
• REMM clinical guidance focuses mainly on mass casualty radiation emergencies. In the absence of formal, prospective research on optimal guidelines for diagnosis and treatment of fever and neutropenia during large, mass casualty radiation emergencies, REMM citations and links on this topic are largely based on peer-reviewed publications in clinical oncology and expert opinion. These links and citations serve as background information only. No uniformly accepted clinical guidance exists for optimal regimens during large mass casualty radiation emergencies, especially when adequate resources may be inadequate at least initially, and crisis standards of care may be implemented.
• See REMM’s Fever and Neutropenia sections in the Template for Hospital Orders in adults and children. Treatment options are offered by REMM and RITN experts as guidance, but no specific regimen is officially endorsed. Every patient should be managed individually, with the resources and information available at the time the patient is seen.

See REMM information about Acute Radiation Syndrome, Exposure Algorithm, Dose Estimation, Time-Dose Effects, Crisis Standards of Care

Children

• Lekshminarayanan A, Bhatt P, Linga VG, Chaudhari R, Zhu B, Dave M, Donda K, Savani S, Patel SV, Billimoria ZC, Bhaskaran S, Zaid-Kaylani S, Dapaah-Siakwan F, Bhatt NS. National Trends in Hospitalization for Fever and Neutropenia in Children with Cancer, 2007-2014. J Pediatr. 2018 Nov;202:231-237. [PubMed Citation]
• Moody KM, Baker RA, Santizo RO, Olmez I, Spies JM, Buthmann A, Granowetter L, Dulman RY, Ayyanar K, Gill JB, Carroll AE. A randomized trial of the effectiveness of the neutropenic diet versus food safety guidelines on infection rate in pediatric oncology patients. Pediatr Blood Cancer. 2018 Jan;65(1). [PubMed Citation]
• Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, Carlesse F, Groll AH, Haeusler GM, Santolaya M, Steinbach WJ, Castagnola E, Davis BL, Dupuis LL, Gaur AH, Tissing WJE, Zaoutis T, Phillips R, Sung L. Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. J Clin Oncol. 2017 Jun 20;35(18):2082-2094. [PubMed Citation]
• Robinson PD, Lehrnbecher T, Phillips R, Dupuis LL, Sung L. Strategies for Empiric Management of Pediatric Fever and Neutropenia in Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: A Systematic Review of Randomized Trials. J Clin Oncol. 2016 Jun 10;34(17):2054-60. [PubMed Citation]
• Haeusler GM, Sung L, Ammann RA, Phillips B. Management of fever and neutropenia in paediatric cancer patients: room for improvement? Curr Opin Infect Dis. 2015 Dec;28(6):532-8. [PubMed Citation]
• Miedema KG, Tissing WJ, Abbink FC, Ball LM, Michiels EM, van Vliet MJ, de Vries WY, Kamps WA, Norbruis OF, Fiocco M, de Groot-Kruseman HA, van de Wetering MD, de Bont ES. Risk-adapted approach for fever and neutropenia in paediatric cancer patients--a national multicentre study. Eur J Cancer. 2016 Jan;53:16-24. [PubMed Citation]
• Vedi A, Pennington V, O'Meara M, Stark K, Senner A, Hunstead P, Adnum K, Londall W, Maurice L, Wakefield C, Cohn RJ. Management of fever and neutropenia in children with cancer. Support Care Cancer. 2015 Jul;23(7):2079-87. [PubMed Citation]

Adults

• Patel K, West HJ. Febrile Neutropenia: Information for Patients. JAMA Oncol. 2017 Dec 1;3(12):1751. [PubMed Citation]
• Stern A, Carrara E, Bitterman R, Yahav D, Leibovici L, Paul M. Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer. Cochrane Database Syst Rev. 2019 Jan 3;1:CD012184. [PubMed Citation]
• Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston KV, Strasfeld L, Flowers CR. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol. 2018 Sep 4:JCO1800374. [PubMed Citation]
• Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston K, Strasfeld L, Flowers CR. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol. 2018 May 10;36(14):1443-1453. [PubMed Citation]
• NCCN Clinical Practice Guidelines in Oncology®: Prevention and Treatment of Cancer-Related Infections, Version 1.2019 – October 25, 2019.
  • Navigation to the page: Home page > NCCN Guidelines® > NCCN Guidelines for Supportive Care > Prevention and Treatment of Cancer-Related Infections (Requires registration to access the pdf guideline.)
  • See information on diagnosis as well as antibacterial, antifungal and antiviral agents
• Mellinghoff SC, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M, Hasenkamp J, Kiehl M, Koldehoff M, Krause SW, Lehners N, von Lilienfeld-Toal M, Löhnert AY, Maschmeyer G, Teschner D, Ullmann AJ, Penack O, Ruhnke M, Mayer K, Ostermann H, Wolf HH, Cornely OA. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol. 2018 Feb;97(2):197-207. [PubMed Citation]
• Heinz WJ, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely OA, Einsele H, Karthaus M, Link H, Mahlberg R, Neumann S, Ostermann H, Penack O, Ruhnke M, Sandherr M, Schiel X, Vehreschild JJ, Weissinger F, Maschmeyer G. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2017 Nov;96(11):1775-1792. [PubMed Citation]
• van Dalen EC, Mank A, Leclercq E, Mulder RL, Davies M, Kersten MJ, van de Wetering MD. Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. Cochrane Database Syst Rev. 2016 Apr 24;4:CD006247. [PubMed Citation]
• Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia:ESMO Clinical Practice Guidelines. Ann Oncology, 2016;27(suppl 5):v111-v118. (European Society for Medical Oncology, ESMO)
• Krzyzanowska MK, Walker-Dilks C, Atzema C et al., Approach to fever assessment in ambulatory cancer patients receiving chemotherapy: a clinical practice guideline. Curr Oncol 2016; 23(4):280-285. [PubMed Citation]